-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This week, the Science and Technology Innovation Board will usher in another innovative drug company meeting, that is, Yifang Biotechnology (Shanghai) Co.
, Ltd.
(hereinafter referred to as Yifang Bio), which will be held on January 20
.
It is worth mentioning that this is the second meeting of Yifang Biology since the meeting was postponed on December 2, 2021
.
Yifang Bio is an innovative drug research and development company, focusing on major diseases such as tumors and metabolic diseases
.
The company was co-founded by several returnees such as Dr.
Yaolin Wang.
The core R&D team has an average of more than 20 years of experience in leading new drug R&D and team management in multinational pharmaceutical companies
.
With the concept of solving unmet clinical needs, Yifang Bio is committed to developing innovative drugs with independent intellectual property rights, created in China and facing the world, and persistently providing patients with safer, more effective and affordable treatment options
.
From the perspective of R&D pipeline, the company currently has 3 core products in the clinical trial stage and 5 pre-clinical research projects, of which 3 core products have been approved for Phase II or Phase III clinical trials, and the research and development progress is ahead
.
In addition, the company also has 1 externally authorized product, which is expected to bring benefits to the company after being approved for listing
.
Since all products of Yifang Bio are in the research and development stage and have not yet been commercialized for production and sales, the company is currently in a state of unprofitable and accumulated unrecovered losses
.
Financial data shows that in 2018, 2019, 2020 and January-June 2021, Yifang Bio's net profit attributable to the company's shareholders was -103 million yuan, -94.
9859 million yuan, -1.
053 billion yuan and -167 million yuan respectively.
The net profit attributable to shareholders of the company after deducting non-recurring gains and losses was -47.
0311 million yuan, -9.
4263 million yuan, -211 million yuan and -167 million yuan.
As of June 30, 2021, Yifang Bio has accumulated no The distributed profit was -1.
346 billion yuan
.
This time Yifang Bio chose to go public with the fifth set of listing standards on the Science and Technology Innovation Board
.
Moreover, the company stated that it cannot guarantee profitability in the next few years.
It is expected that it will not be able to pay dividends in the short term after listing, and it may even face the risk of delisting after listing.
.
On December 2, 2021, Yifang Biotech had a meeting, and the company was suspended from consideration at that time
.
At the meeting, the Listing Committee expressed concern about the factual situation of the issuer and Jiang Yueheng's related patent and trade secret disputes and the progress of the new litigation, whether it will have a material adverse impact on the issuer, and the issuer's response measures
.
At the same time, the issuer's representative is required to explain the specific content, necessity and rationality of the fund-raising project "Effective Biological Headquarters Base Construction" in combination with the company's development strategy plan and business model
.
Since the launch of the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019, new financing channels have opened up for unprofitable biomedical innovation companies.
In recent years, the "IPO financing wave" has continued to surge.
According to statistics, pharmaceutical companies that successfully landed on the A-share Science and Technology Innovation Board in 2021 A total of 38, an increase of 10 from 28 in 2020
.
It is worth mentioning that since the second half of 2021, the biopharmaceutical sector has begun to "cool down", and the news of biopharmaceutical companies' IPO "breaking" has continued.
According to statistics, since 2021, 6 new pharmaceutical and biological stocks have broken on the first day of listing.
, accounting for more than 40%
.
And just last week, Asieris Pharmaceuticals landed on the Science and Technology Innovation Board and broke at the opening
.
In general, the industry believes that China's pharmaceutical innovation market has shifted from focusing on scale to focusing on quality.
The era of easy money for pharmaceutical companies has passed, and it is necessary to focus on the core in order to go more stable and farther
.
, Ltd.
(hereinafter referred to as Yifang Bio), which will be held on January 20
.
It is worth mentioning that this is the second meeting of Yifang Biology since the meeting was postponed on December 2, 2021
.
Yifang Bio is an innovative drug research and development company, focusing on major diseases such as tumors and metabolic diseases
.
The company was co-founded by several returnees such as Dr.
Yaolin Wang.
The core R&D team has an average of more than 20 years of experience in leading new drug R&D and team management in multinational pharmaceutical companies
.
With the concept of solving unmet clinical needs, Yifang Bio is committed to developing innovative drugs with independent intellectual property rights, created in China and facing the world, and persistently providing patients with safer, more effective and affordable treatment options
.
From the perspective of R&D pipeline, the company currently has 3 core products in the clinical trial stage and 5 pre-clinical research projects, of which 3 core products have been approved for Phase II or Phase III clinical trials, and the research and development progress is ahead
.
In addition, the company also has 1 externally authorized product, which is expected to bring benefits to the company after being approved for listing
.
Since all products of Yifang Bio are in the research and development stage and have not yet been commercialized for production and sales, the company is currently in a state of unprofitable and accumulated unrecovered losses
.
Financial data shows that in 2018, 2019, 2020 and January-June 2021, Yifang Bio's net profit attributable to the company's shareholders was -103 million yuan, -94.
9859 million yuan, -1.
053 billion yuan and -167 million yuan respectively.
The net profit attributable to shareholders of the company after deducting non-recurring gains and losses was -47.
0311 million yuan, -9.
4263 million yuan, -211 million yuan and -167 million yuan.
As of June 30, 2021, Yifang Bio has accumulated no The distributed profit was -1.
346 billion yuan
.
This time Yifang Bio chose to go public with the fifth set of listing standards on the Science and Technology Innovation Board
.
Moreover, the company stated that it cannot guarantee profitability in the next few years.
It is expected that it will not be able to pay dividends in the short term after listing, and it may even face the risk of delisting after listing.
.
On December 2, 2021, Yifang Biotech had a meeting, and the company was suspended from consideration at that time
.
At the meeting, the Listing Committee expressed concern about the factual situation of the issuer and Jiang Yueheng's related patent and trade secret disputes and the progress of the new litigation, whether it will have a material adverse impact on the issuer, and the issuer's response measures
.
At the same time, the issuer's representative is required to explain the specific content, necessity and rationality of the fund-raising project "Effective Biological Headquarters Base Construction" in combination with the company's development strategy plan and business model
.
Since the launch of the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019, new financing channels have opened up for unprofitable biomedical innovation companies.
In recent years, the "IPO financing wave" has continued to surge.
According to statistics, pharmaceutical companies that successfully landed on the A-share Science and Technology Innovation Board in 2021 A total of 38, an increase of 10 from 28 in 2020
.
It is worth mentioning that since the second half of 2021, the biopharmaceutical sector has begun to "cool down", and the news of biopharmaceutical companies' IPO "breaking" has continued.
According to statistics, since 2021, 6 new pharmaceutical and biological stocks have broken on the first day of listing.
, accounting for more than 40%
.
And just last week, Asieris Pharmaceuticals landed on the Science and Technology Innovation Board and broke at the opening
.
In general, the industry believes that China's pharmaceutical innovation market has shifted from focusing on scale to focusing on quality.
The era of easy money for pharmaceutical companies has passed, and it is necessary to focus on the core in order to go more stable and farther
.
